relapsed/refractory acute myeloid leukemia research hub

A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)

This study is looking at a new way to treat acute myeloid leukaemia (AML) in older patients where other treatments haven't worked or stopped working. It combines two medicines, mebendazole and Ara-C, to see if they are safe and effective together.